Previous 10 | Next 10 |
Global Blood Therapeutics Inc. (NASDAQ:GBT) traded today at a new 52-week low of $28.88. This new low was reached on below average trading volume as 153,000 shares traded hands, while the average 30-day volume is approximately 1.5 million shares. Global Blood Therapeutics Inc operates in...
Shares of Global Blood Therapeutics Inc. (NASDAQ:GBT) traded at a new 52-week low today of $29.85. This new low was reached on below average trading volume as 153,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Potential upside of 1.2% exists...
Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta ® (voxelotor) in Children with SCD Ages 4 to 11 Initiates Phase 3 Clinical Trials of Inclacumab and Enrolls First SCD Patient in Phase 1 Study of GBT021601 SOUTH SAN FRANCISCO, Calif., J...
Shares of Global Blood Therapeutics Inc. (NASDAQ:GBT) traded at a new 52-week low today of $31.25. So far today approximately 153,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares. Global Blood Therapeutics Inc. (NASDAQ:GBT) defies analysts wit...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Shares of Global Blood Therapeutics (NASDAQ: GBT) closed at $35.02 on Wednesday, up 7.9% from the day before and rebounding two days after the stock hit a 52-week low at $31.90. The move is simply a correction to an overcorrection as investors saw a bargain available once the st...
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) has awarded approximately $450,000 to U.S. community-based organizations and institutions as part of the company’s 2021 Access to Excellent Care for Sickle Ce...
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced toda...
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE)...
Global Blood Therapeutics (GBT) says that on June 1, 2021, the compensation committee of GBT's board granted 11 new employees options to purchase an aggregate of 35,500 shares of the company's common stock at $37.20/share and restricted stock units for an aggregate of 45,410 shares of th...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...